MedTrace Logo

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer

NCT03013712 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-01-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.

Conditions

Interventions

BIOLOGICAL

CAR-T cell immunotherapy

This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.

Sponsors & Collaborators

  • First Affiliated Hospital of Chengdu Medical College

    lead OTHER

Principal Investigators

  • Xiao-an Li, PhD · First Affiliated Hospital of Chengdu Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03013712 on ClinicalTrials.gov